271 related articles for article (PubMed ID: 32127003)
1. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
2. Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.
Jin Y; Zhang P; Wang Y; Jin B; Zhou J; Zhang J; Pan J
Clin Cancer Res; 2018 Aug; 24(15):3741-3754. PubMed ID: 29233905
[No Abstract] [Full Text] [Related]
3. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.
Zhang J; Liu S; Ye Q; Pan J
Mol Cancer; 2019 Sep; 18(1):140. PubMed ID: 31526394
[TBL] [Abstract][Full Text] [Related]
4. Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma.
Zhou J; Liu S; Wang Y; Dai W; Zou H; Wang S; Zhang J; Pan J
Mol Cancer; 2019 Nov; 18(1):159. PubMed ID: 31718679
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
7. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Landreville S; Agapova OA; Matatall KA; Kneass ZT; Onken MD; Lee RS; Bowcock AM; Harbour JW
Clin Cancer Res; 2012 Jan; 18(2):408-16. PubMed ID: 22038994
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-137 targets EZH2 to exert suppressive functions in uveal melanoma via regulation of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition.
Zhang J; Liu G; Jin H; Li X; Li N; Yin Q; Hu R
J BUON; 2021; 26(1):173-181. PubMed ID: 33721449
[TBL] [Abstract][Full Text] [Related]
10. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
[TBL] [Abstract][Full Text] [Related]
11. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
12. LncRNA PVT1 knockdown affects proliferation and apoptosis of uveal melanoma cells by inhibiting EZH2.
Huang XM; Shi SS; Jian TM; Tang DR; Wu T; Sun FY
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2880-2887. PubMed ID: 31002139
[TBL] [Abstract][Full Text] [Related]
13. miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma.
Li J; Liu X; Li C; Wang W
J Cell Biochem; 2019 Aug; 120(8):12412-12421. PubMed ID: 30825222
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of microRNA-130a represses uveal melanoma cell migration and invasion through inactivation of the Wnt/β-catenin signaling pathway by downregulating USP6.
Wu S; Han M; Zhang C
Cancer Gene Ther; 2022 Jul; 29(7):930-939. PubMed ID: 34522027
[TBL] [Abstract][Full Text] [Related]
15. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma.
Dai W; Liu S; Wang S; Zhao L; Yang X; Zhou J; Wang Y; Zhang J; Zhang P; Ding K; Li Y; Pan J
Signal Transduct Target Ther; 2021 May; 6(1):176. PubMed ID: 33976105
[TBL] [Abstract][Full Text] [Related]
16. The role of RASSF1A in uveal melanoma.
Dratviman-Storobinsky O; Cohen Y; Frenkel S; Merhavi-Shoham E; El SD; Binkovsky N; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2012 Oct; 53(6):2611-9. PubMed ID: 22447862
[TBL] [Abstract][Full Text] [Related]
17. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
18. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
Han A; Purwin TJ; Bechtel N; Liao C; Chua V; Seifert E; Sato T; Schug ZT; Speicher DW; Harbour JW; Aplin AE
Oncogene; 2021 Jan; 40(3):618-632. PubMed ID: 33208912
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
20. CD166high Uveal Melanoma Cells Represent a Subpopulation With Enhanced Migratory Capacity.
Djirackor L; Kalirai H; Coupland SE; Petrovski G
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2696-2704. PubMed ID: 31242292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
